Psilocybin

Browse filters
Active filters:Psilocybin xClear all
Ololiuhqui, Peyotl, and Teonanácatl in the Florentine Codex

Ololiuhqui, Peyotl, and Teonanácatl in the Florentine Codex

Sahagún’s Book 11 on herbs that intoxicate

Spanish entries from Book 11 of the Florentine Codex, the encyclopedia of Nahua life compiled by Bernardino de Sahagún and Nahua scholars at Tlatelolco around 1577. They describe ololiuhqui, peyotl, tlapatl, mixitl, and teonanácatl, plants and mushrooms that cause intoxication or visions, with an English translation made for the archive.

The Elements of Mazatec Witchcraft

The Elements of Mazatec Witchcraft

A Berkeley anthropologist's field survey of Mazatec witchcraft from a 1938 expedition to Huautla de Jiménez, Oaxaca. Hosted here is a fair-use excerpt: Johnson's eyewitness account of a curing ceremony he and his party attended on July 16, 1938 -- the first outsider-witnessed session involving the sacred mushrooms -- along with his description of the mushroom species and their ritual use among Mazatec brujos.

External source
The Psychedelic Review, Vol. I, No. 1

Psychedelic Review, No. 1

The founding issue of The Psychedelic Review, published in June 1963 by Timothy Leary and Ralph Metzner's International Federation for Internal Freedom. Hosted here are the issue's unsigned Editorial and Statement of Purpose, which set out the journal's program and explain its choice of the word 'psychedelic.' The issue's bylined articles, by Gerald Heard, R. Gordon Wasson, and Alan Watts, are described in the front matter but not reproduced.

Testimony of Allen Ginsberg on LSD before a Special Subcommittee of the Senate Committee on the Judiciary

Ginsberg Senate Testimony on LSD (1966)

The poet Allen Ginsberg (1926–1997) testified on June 14, 1966, before the special Senate Judiciary subcommittee holding hearings on narcotic rehabilitation and LSD on college campuses, with Quentin N. Burdick (1908–1992) presiding. He read a long prepared statement describing his visionary experience of 1948 and his use of peyote, mescaline, LSD, and ayahuasca, then argued from newspaper coverage and the medical literature that LSD's dangers had been exaggerated and that research should be expanded. The record hosts the full printed text, pp. 487–509, including his questioning by Burdick and Jacob K. Javits (1904–1986), his list of proposed research topics (Exhibit No. 76), and the references he put into the record.

Psychedelic Drugs: Considerations for Clinical Investigations (Guidance for Industry)

FDA Psychedelic Drugs Guidance

Considerations for Clinical Investigations (Guidance for Industry)

FDA guidance (July 2026) for sponsors developing psychedelics—5-HT2A agonists including psilocybin and LSD, plus MDMA—as approved medicines. It addresses the regulatory pathway for Schedule I drugs in clinical trials and identifies methodological challenges: perceptual effects complicate blinding ('functional unblinding'), and the independent contribution of psychotherapy paired with dosing remains uncharacterized.